Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0TAOLW
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
lY203725
|
|||||
| Synonyms |
LY203725
Click to Show/Hide
|
|||||
| Organization |
Eli Lilly (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
4-6
|
|||||
| Structure |
|
|||||
| Antibody Name |
KS1/4
|
Antibody Info | Antigen Name |
Undisclosed
|
||
| Payload Name |
4-desacetylvinblastine (DAVLB)
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Random Lysines
|
|||||
| Combination Type |
KS1/4-DAVLB
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Ovarian cancer |
1 Trials
|